AAV2/4-RS1 gene therapy in the retinoschisin knockout mouse model of X-linked retinoschisis.

There was a highly significant subretinal treatment effect on ERG amplitudes collectively at 7–9 months post-injection (p = 0.0003).

also in 132,142 other papers

22.56; p = 0.0193, q = 0.0590) The percentage difference between treated and untreated eyes showed a trend for more effect of gene therapy on cone predominant amplitudes (light-adapted and flicker) than for rod predominant amplitudes (dark-adapted), though this was not statistically significantly different (p = 0.8844, two-sample t test).

also in 53,322 other papers